中华航海医学与高气压医学杂志
中華航海醫學與高氣壓醫學雜誌
중화항해의학여고기압의학잡지
CHINESE JOURNAL OF NAUTICAL MEDICINE AND HYPERBARIC MEDICINE
2011年
4期
211-213
,共3页
姜领%林少华%楚存坤%孔爱君%鞠衍松
薑領%林少華%楚存坤%孔愛君%鞠衍鬆
강령%림소화%초존곤%공애군%국연송
心衰%高压氧%射血分数%内皮细胞功能
心衰%高壓氧%射血分數%內皮細胞功能
심쇠%고압양%사혈분수%내피세포공능
Heart failure%Hyperbaric oxygen%Ejection fraction%Endothelin function
目的 研究高压氧对左心室射血分数(LVEF)正常的心力衰竭患者血浆中一氧化氮(NO)、降钙素基因相关肽(CGRP)、内皮素(ET)和抵抗素的影响。方法 将67例左心室射血分数正常的心力衰竭患者分为高压氧组（33例）与对照组（34例）。治疗前后分别检测血浆中NO、CGRP、ET和抵抗素的水平。结果 与治疗前比较，高压氧与对照组治疗后血浆中NO[(84.61±25.64)、(56.41±22.53) mg/L]、CGRP[(51.71±12.98)、(35.98±10.47) mg/L]、ET[(55.94±9.65)、(75.14±11.23)mg/L]和抵抗素[(24.60±6.78)、(27.40±4.68) μg/L]水平均明显改善(P＜0.05)，且以高压氧组改善更加明显。高压氧组与对照组治疗后比较差异有统计学意义(P＜0.05或P＜0.01)。结论 高压氧能显著改善LVEF正常的心力衰竭患者的NO、CGRP、ET和抵抗素的代谢失衡，改善内皮细胞功能。
目的 研究高壓氧對左心室射血分數(LVEF)正常的心力衰竭患者血漿中一氧化氮(NO)、降鈣素基因相關肽(CGRP)、內皮素(ET)和牴抗素的影響。方法 將67例左心室射血分數正常的心力衰竭患者分為高壓氧組（33例）與對照組（34例）。治療前後分彆檢測血漿中NO、CGRP、ET和牴抗素的水平。結果 與治療前比較，高壓氧與對照組治療後血漿中NO[(84.61±25.64)、(56.41±22.53) mg/L]、CGRP[(51.71±12.98)、(35.98±10.47) mg/L]、ET[(55.94±9.65)、(75.14±11.23)mg/L]和牴抗素[(24.60±6.78)、(27.40±4.68) μg/L]水平均明顯改善(P＜0.05)，且以高壓氧組改善更加明顯。高壓氧組與對照組治療後比較差異有統計學意義(P＜0.05或P＜0.01)。結論 高壓氧能顯著改善LVEF正常的心力衰竭患者的NO、CGRP、ET和牴抗素的代謝失衡，改善內皮細胞功能。
목적 연구고압양대좌심실사혈분수(LVEF)정상적심력쇠갈환자혈장중일양화담(NO)、강개소기인상관태(CGRP)、내피소(ET)화저항소적영향。방법 장67례좌심실사혈분수정상적심력쇠갈환자분위고압양조（33례）여대조조（34례）。치료전후분별검측혈장중NO、CGRP、ET화저항소적수평。결과 여치료전비교，고압양여대조조치료후혈장중NO[(84.61±25.64)、(56.41±22.53) mg/L]、CGRP[(51.71±12.98)、(35.98±10.47) mg/L]、ET[(55.94±9.65)、(75.14±11.23)mg/L]화저항소[(24.60±6.78)、(27.40±4.68) μg/L]수평균명현개선(P＜0.05)，차이고압양조개선경가명현。고압양조여대조조치료후비교차이유통계학의의(P＜0.05혹P＜0.01)。결론 고압양능현저개선LVEF정상적심력쇠갈환자적NO、CGRP、ET화저항소적대사실형，개선내피세포공능。
Objective To study the effect of HBO on the levels of plasma nitric oxide (NO), calcitonin gene-related peptide( CGRP), endothelin (ET) and resistin in the patients with heart failure and normal left ventricle ejection fraction. Methods A total of 67 patients with heart failure and normal ejection fraction were randomly divided into the control group ( n = 33) and the HBO group ( n = 34). Levels of plasma NO[(84.61 ±25.64)、(56.41 ± 22.53) mg/L]、CGRP[(51.71 ± 12.98)、(35.98 ± 10.47) mg/L]、ET [(55.94±9.65)、(75. 14 ± 11.23) mg/L]and resistin[(24.60 ±6.78)、(27.40 ±4.68) μg/L]were measured before and after treatment. Results After treatment, the levels of plasma NO, calcitonin gene-related peptide, endothelin and resistin in the patients with heart failure and normal ejection fraction improved obviously for both groups, with more significant improvement for the HBO group. Following treatment, statistical differences in the therapeutic effects could be seen, when comparisons were made between the HBO group and the control group( P ＜ 0. 05 or P ＜ 0. 01 ). Conclusions HBO could obviously improve the metabolic imbalance of NO, CGRP, ET and resistin and enhance the vascular endothelial function in the patients with heart failure and normal left ventricle ejection fraction.
